The high mobility group A2 (HMGA2), an oncofetal protein, was shown to play a role in tumor development and progression. However, the molecular and clinical role of HMGA2 in epithelial ovarian carcinomas (EOCs) is still unknown. In the present study, EOC cell line SKOV3 was subjected to in vitro assays. Here, our findings showed that HMGA2 was highly expressed in EOC cell line SKOV3. HMGA2 knockdown promoted cell apoptosis and the cleavage of caspase 3, and decreased the B cell lymphoma 2 (Bcl-2)/Bax ratio in SKOV3. Functionally, HMGA2 knockdown resulted in reduction of SKOV3 cell migration and invasion. Mechanically, HMGA2 knockdown affected the occurrence of EMT by increasing E-cadherin gene and protein expression and decreasing the gene and protein expression of N-cadherin, slug, and vimentin. At the same time, HMGA2 also repressed the expression of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), which was consistent with the decreased invasion capacity. In conclusion, HMGA2 is associated with migration and invasiveness and regulates the progression of EMT in the development of EOC, and HMGA2 gene and protein may be a novel therapeutic target against EOC in the clinical practice.
HMGA2 Epithelial ovarian carcinomas EMT
This is a preview of subscription content, log in to check access.
We greatly thank other members of Yang Lab for valuable suggestions and writing.
Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther. 2010;10:81–8.CrossRefPubMedGoogle Scholar
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Gynecologic Oncology Group Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.CrossRefPubMedGoogle Scholar
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.CrossRefPubMedGoogle Scholar
Chiappetta G, Ammirante M, Basile A, et al. The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab. 2007;92:1159–63.CrossRefPubMedGoogle Scholar
Gentilella A, Passiatore G, Deshmane S, et al. Activation of BAG3 by Egr-1 in response to FGF-2 in neuroblastoma cells. Oncogene. 2008;27:5011–8.CrossRefPubMedGoogle Scholar
Staibano S, Mascolo M, Benedetto M, et al. BAG3 protein delocalization in prostate carcinoma. Tumor Biol. 2010;31:461–9.CrossRefGoogle Scholar
Wang HQ, Meng X, Gao Y-Y, et al. Characterization of BAG3 cleavage during apoptosis of pancreatic cancer cells. J Cell Physiol. 2010;224:94–100.PubMedGoogle Scholar
Suzuki M, Iwasaki M, Sugio A, et al. BAG3 (BCL2-associated athanogene 3) interacts with MMP-2 to positively regulate invasion by ovarian carcinoma cells. Cancer Lett. 2011;303:65–71.CrossRefPubMedGoogle Scholar
Rosati A, Graziano V, De Laurenzi V, et al. BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis. 2011;7:141.CrossRefGoogle Scholar
Falco A, Festa M, Basile A, et al. BAG3 controls angiogenesis through regulation of ERK phosphorylation. Oncogene. 2012;31:5153–61.CrossRefPubMedGoogle Scholar
Li N, Du ZX, Zong ZH, et al. PKC[delta]-mediated phosphorylation of BAG3 at Ser187 site induces epithelial-mesenchymal transition and enhances invasiveness in thyroid cancer FRO cells. Oncogene. 2012;32:4539–48.CrossRefPubMedGoogle Scholar
Déry M-AC, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol. 2005;37:535–40.CrossRefPubMedGoogle Scholar
De A, De A, Papasian C, et al. Extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors. PLoS One. 2013;8:e72748.CrossRefPubMedPubMedCentralGoogle Scholar
Kim KW, Paul P, Qiao J, et al. Enhanced autophagy blocks angiogenesis via degradation of gastrin-releasing peptide in neuroblastoma cells. Autophagy. 2013;9:1579–90.CrossRefPubMedGoogle Scholar
Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell inter-actions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541–73.CrossRefPubMedGoogle Scholar